SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
Recruiting · NCT04527419 · Interventional (participants receive a specific treatment) · Lead sponsor: Fudan University
View the official record on ClinicalTrials.gov →Interventions studied
No mediastinal lymph node dissection
What this trial is about
This is a study from Eastern Cooperative Thoracic Oncology Project, numbered as ECTOP-1009. Systematically mediastinal lymph node dissection or not in clinical stage T1 ground-glass dominated invasive lung adenocarcinoma: a multi-center, prospective clinical trial
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Clinical stage T1N0M0 and planned curative surgery.
- A single lesion detected on computed tomography (CT) scan featured as ground glass nodule(GGO) and C/T ratio ≤0.5.
- Age 18 to 75.
- Patients who have signed the informed consent form.
Exclusion criteria
- Other than invasive adenocarcinoma by pathological analysis.
- Patients undergoing wedge resection but not meeting the specific conditions of a Consolidation/Tumor Ratio (CTR) ≤ 0.25 AND a maximum tumor diameter ≤ 2 cm, based on the oncological outcomes of the JCOG0804/WJOG4507L trial.
- Not complete resected or curative intent.
- Patients who have history of other malignant tumors.
- Patients who have history of thoracic surgery.
- Patients who have received radiation, chemotherapy or other treatments previously.
Where it is running
1 location listed.
- Fudan University Shanghai Cancer Center - Shanghai, China